M1/M2 polarization of Lyz2Cre+ or C57Bl/6 BMDMs yield unique phenotypes when polarized in the presence/absence of EGFR inhibitor Erlotinib

We report the gene expression (obtained by next generation RNAseq) of bone marrow derived macrophages from Lyz2Cre+ or C57Bl/6 mice that have been polarized to an M1 or M2 phenotype in the presence of absence of EGFR inhibitor, Erlotinib. This study provides data on how M1 and M2 BMDMs differ in their overall gene expression profiles in mice as well as how gene expression is influenced by EGFR inhibition during polarization. BMDMs derived from Lyz2Cre+ or C57Bl/6 mice were treated with LPS (100ng/ml)+IFNg (50ng/ml) to achieve an M1 phenotype and with IL-4 (10ng/ml)+IL13 (10ng/ml) to achieve an M2 phenotype. BMDMs receiving erlotinib treatment were given erlotinib (1uM) at time of M1/M2 polarization

本研究报道了经下一代RNA测序（next generation RNAseq）获得的骨髓来源巨噬细胞（bone marrow derived macrophages, BMDMs）的基因表达谱，这些细胞取自Lyz2Cre+或C57Bl/6小鼠，并在存在或不存在表皮生长因子受体（epidermal growth factor receptor, EGFR）抑制剂厄洛替尼（Erlotinib）的条件下被极化为M1或M2表型。本数据集阐明了小鼠体内M1与M2型BMDMs的整体基因表达谱差异，同时揭示了极化过程中EGFR抑制对基因表达的调控作用。取自Lyz2Cre+或C57Bl/6小鼠的BMDMs，分别经脂多糖（lipopolysaccharide, LPS，100ng/ml）+干扰素γ（interferon gamma, IFNγ，50ng/ml）诱导极化为M1表型，经白细胞介素4（interleukin-4, IL-4，10ng/ml）+白细胞介素13（interleukin-13, IL-13，10ng/ml）诱导极化为M2表型。接受厄洛替尼处理的BMDMs，在M1/M2极化启动时加入终浓度为1μM的厄洛替尼。